HealthDay - THURSDAY, April 7 (HealthDay News) -- Vandetanib has been approved by the U.S. Food and Drug Administration as the first drug to treat a rare form of thyroid cancer in its latter stages.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.